Background & Objective: Imbalance in histone acetylation levels and consequently the
dysfunction in transcription are associated with a wide variety of neurodegenerative diseases. Histone
proteins acetylation and deacetylation is carried out by two opposite acting enzymes, histone acetyltransferases
and histone deacetylases (HDACs), respectively. In-vitro and in-vivo animal models of
neurodegenerative diseases and post mortem brains of patients have been reported overexpressed level
of HDACs. In recent past numerous studies have indicated that HDAC inhibitors (HDACIs) might be
a promising class of therapeutic agents for treating these devastating diseases. HDACs being a part of
repressive complexes, the outcome of their inhibition has been attributed to enhanced gene expression
due to heightened histone acetylation. Beneficial effects of HDACIs has been explored both in preclinical
and clinical studies of these diseases. Thus, their screening as future therapeutics for neurodegenerative
diseases has been widely explored.
Conclusion: In this review, we focus on the putative role of HDACs in neurodegeneration and further
discuss their potential as a new therapeutic avenue for treating neurodegenerative diseases.
Keywords: Alzheimer’s disease, HDAC, Histone deacetylases inhibitors, Huntington’s disease, Parkinson’s disease, SAHA,
Rights & PermissionsPrintExport